Scott A. Hepford is Co-Founder and CEO of Well Cell Global LLC and Well Cell Support LLC, which are multinational healthcare innovation companies that operate under the names Diabetes Relief, RestorMetabolix, Diabetes Relax, and Diabetes Relief Middle East in 40 locations in the USA, Turkey, Azerbaijan, and Lebanon, with additional sites underway. Well Cell’s primary mission is to provide its groundbreaking processes to physicians worldwide, assist in achieving better clinical outcomes, and reduce healthcare costs. To serve millions of patients, Well Cell licenses its patented Physician-Directed Physiologic Insulin Resensitization modality to trained, certified providers. This adjunct modality administers insulin as a hormone rather than a drug as it addresses the primary cause of Diabetes, metabolic failure. By utilizing insulin in a manner that bio-mimics normal physiology, insulin resistance is reduced, helping blood sugar more readily enter each cell and be converted into energy.
Scott A. Hepford is a seasoned entrepreneur, operations executive and biotech innovator with 20+ years’ experience managing and growing public and private companies. His experience spans several industries, including Healthcare, Financial Services, Manufacturing, Private Equity, Oil & Gas, Global Travel, and Information Technology. He has served as a Fortune 100 executive and has grown companies, divisions, products, and programs. He holds issued patents and trademarks in the Healthcare industry and has consulted for companies ranging from the Fortune 10 to the fortune someday. Hepford enjoys building highly effective teams through hands-on collaboration and service-based leadership principles.